Auckland Uniservices Limited

Health Innovation Ventures B.v.

Victoria Link Limited

Guangzhou Institute of Biomedicine and Health

Achilles Medical Limited

Convert Pharmaceuticals Sa

Christopher Paul Guise

Jeffrey Bruce Smaill

Adam Vorn Patterson

Amir Ashoorzadeh

David Francis Ackerley

Janine Naomi Copp

Alexandra Marie Mowday

Elsie May Williams

Matthew Roy Bull

Ke Ding

Swarnalatha Akuratiya Gamage

Zhengchao Tu

Jack Urquhart Flanagan

Xiaomei Ren

Christopher John Squire

Victoria Jackson

Angus Cheverton Grey

Tillman Pearce

Xueqiang Li

Nipun Davar

Gareth Adrian Prosser

Shuang Jiang

Sophie Phillipa Syddall

Maria Rosaria Abbattista

Shevan Silva

AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders. 

Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders

Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.

FGFR kinase inhibitors and pharmaceutical uses

Compositions containing and methods of administering TH-4000 are useful in treatment of cancer alone or in combination with other anti-cancer agents.

Kinase inhibitor prodrug for the treatment of cancer

The invention relates generally to bacterial nitroreductase enzymes and methods of use thereof: more particularly, although not exclusively, the enzymes have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy. The invention also relates to the use of bacterial nitroreductase enzymes in radioimaging and/or ablation of biological agents and to compositions of use in such methods.

Bacterial nitroreductase enzymes and methods relating thereto

The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.

Prodrugs and methods of use thereof

Growing community of inventors

Auckland, New Zealand

Christopher Paul Guise